Minimizing drug interactions

NutrientDrug Interactions

Drug Approvals

In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in e...

CMV Antisense Drug

Bcl-2 Antisense Drug

Drug-Drug Interactions Still High in the Medical ICU

Potentially significant drug interactions may be missed by the current alerting system in intensive care units. Medscape Medical News

Minimal Metabolism with Other Drugs Makes a Difference with This Statin, Part 2: Drug–Drug Interactions

Pitavastatin, a synthetic HMG-CoA reductase inhibitor, is minimally metabolized by the cytochrome P-450 (CYP) isozymes and is associated with a low frequency of drug interactions. Patients treated...

New online tool helps industry identify drug interactions

Drug interactions and drug side effects occur all-too-often in patients' lives. Now there's a new online resource to help guide pharmaceutical developers as they endeavor to improve testing for potent...

Greater awareness of cancer drug interactions called for

Healthcare professionals need to be more aware of the risk of drug-drug interactions in patients taking oral anticancer medicines, say pharmacists in the Netherlands. A study reported in the Briti...

Pharmaceutical Research: Physicochemical Interactions in Solid Dosage Forms

Type: Original PaperComplete characterization and mechanistic understanding of physicochemical interactions in solid dosage forms are not only important for consistent manufacturability, stability, an...

Minimal Metabolism with Other Drugs Makes a Difference with This Statin, References

Pitavastatin, a synthetic HMG-CoA reductase inhibitor, is minimally metabolized by the cytochrome P-450 (CYP) isozymes and is associated with a low frequency of drug interactions. Patients treated...

Minimal Metabolism with Other Drugs Makes a Difference with This Statin, Part 1: Introduction

Pitavastatin, a synthetic HMG-CoA reductase inhibitor, is minimally metabolized by the cytochrome P-450 (CYP) isozymes and is associated with a low frequency of drug interactions. Patients treated...

Minimal Metabolism with Other Drugs Makes a Difference with This Statin, Part 3: Pharmacokinetic Bioequivalence

Pitavastatin, a synthetic HMG-CoA reductase inhibitor, is minimally metabolized by the cytochrome P-450 (CYP) isozymes and is associated with a low frequency of drug interactions. Patients treated...

The development of children's regret and relief.

Previous research found that children first experience regret at 5 years and relief at 7. In two experiments, we explored three possibilities for this lag: (1) relief genuinely develops later than reg...

Herb-drug pharmacokinetic interactions reviewed.

Importance of the field: The global increase in the popularity of alternative medicines has raised renewed concerns regarding herb-drug interactions. These interactions are especially important for dr...

Potential interactions of rheumatologic medications in the elderly.

Improving the safety of prescriptions for elderly patients is of substantial interest for physicians of all specialities as well as for general health policy and health services. Owing to the increase...

Network-based analysis and characterization of adverse drug-drug interactions.

Co-administration of multiple drugs may cause adverse effects, which are usually known but sometimes unknown. Package inserts of prescription drugs are supposed to contain contraindications and warnin...

Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients.

Introduction: Knowledge of drug interactions is vital to maximize antiretroviral efficacy and avoid drug-related toxicities. Treatment of co-morbidities has become a difficult task in HIV-infected ind...